Apricus Biosciences (APRI) Rating Increased to Hold at Zacks Investment Research

Apricus Biosciences (NASDAQ:APRI) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research report issued on Wednesday.

According to Zacks, “Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT ®. Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. The Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. Apricus Bio was formerly known as NexMed, Inc and is headquartered in San Diago, California. “

Separately, HC Wainwright reissued a “buy” rating and set a $4.50 target price on shares of Apricus Biosciences in a research report on Friday, November 3rd.

Apricus Biosciences (NASDAQ:APRI) traded up $0.18 during midday trading on Wednesday, hitting $2.02. The stock had a trading volume of 918,900 shares, compared to its average volume of 569,750. The company has a market cap of $28.00, a P/E ratio of 3.48 and a beta of 0.43. Apricus Biosciences has a 52-week low of $0.86 and a 52-week high of $4.07.

Apricus Biosciences (NASDAQ:APRI) last released its earnings results on Thursday, November 2nd. The company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.15). During the same quarter in the previous year, the company earned ($0.19) earnings per share. equities analysts forecast that Apricus Biosciences will post -0.6 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/03/apricus-biosciences-apri-rating-increased-to-hold-at-zacks-investment-research.html.

About Apricus Biosciences

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

Get a free copy of the Zacks research report on Apricus Biosciences (APRI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply